Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Bullboard Posts
Post by SupermanLanternon Feb 01, 2018 12:03pm
225 Views
Post# 27480265

good news

good news

Bill C-45 is 134 pages long. We have five months left, 16 weeks of work. That’s about nine pages a week. I believe that most Canadians expect an efficient Senate to be able to get that kind of work done. Especially since, as recently as last month, they saw us pass Bill C-63, the Budget Implementation Act — a complex, 317-page enactment — in just 10 days.

Well, you will tell me, of course, that’s true, but this is a different kind of bill. This bill will, in a way, change Canadian society. I would put it in the same category as, say, the medically assisted dying bill, Bill C-14. Counting pre-study, it took us two and a half months to study and pass Bill C-14. Would anyone dare say we did not do a thorough examination of that bill? Again, we have five months to study Bill C-45, twice as much as we had for the medically assisted dying bill.

The introduction of Bill C-45 gave me the opportunity to read the report of the Senate Special Committee on Illegal Drugs. I did so bearing in mind the kind of man its chair, Pierre Claude Nolin, was. Senator Nolin was a Conservative — a conservative of party and of principles — a wise, pragmatic man who would not have endorsed the legalization of cannabis had he not been absolutely convinced, after careful consideration, of the futility and the harmfulness of prohibition.

Colleagues, I don’t expect that you will be influenced by the mundane speech of a rookie senator. Instead, I ask you to stop and reflect on these wise words that Senator Nolin left us in his historic report:

. . . the continued prohibition of cannabis jeopardizes the health and well-being of Canadians much more than the regulated marketing of the substance. . . .

It is time to recognize what is patently obvious: our policies have been ineffective because they are poor policies.

Thank you.

(On motion of Senator Martin, debate adjourned.)

Bullboard Posts